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Abstract: Increased body mass index (BMI), as an approximation of body adiposity, is a risk factor for developing 
several adult malignancies. To quantify these risks, we reported a comprehensive systematic review (Lancet 2008; 371: 
569-78) of prospective observational studies determining associations between BMI and risk of incident cancer for 20 
cancer types. We demonstrated that associations are: (i) sex-specific; (ii) exist for a wider range of malignancies than 
previously thought; and (iii) are broadly consistent across geographic populations. In the present paper, we tested these 
data against the Bradford-Hill criteria of causal association, and argue that the available data support strength of 
association, consistency, specificity, temporality, biological gradient, plausibility, coherence and probably analogy. 
However, the experimental evidence supporting reversibility is currently lacking, though indirect evidence from 
longitudinal data in cohort studies and long-term follow-up post-bariatric surgery is emerging. We additionally assessed 
these data against appropriate adjustment for available confounding factors; measurement error and study design; and 
residual confounding; and found lack of alternative explanations. We conclude that there is considerable evidence to 
support a causal association between BMI and risk for many cancer types, but in order to establish the role of weight 
control in cancer prevention, there is a need to develop trial frameworks in which to better test reversibility. 
Keywords: Body mass index, obesity, cancer risk, causal association. 
INTRODUCTION 
 Increased body mass index (BMI), as an approximation 
of body adiposity, is an established risk factor for developing 
adult malignancies. In 2002, the International Agency for 
Research into Cancer (IACR) [1] concluded, from a semi-
quantitative review of the literature, that excess bodyweight 
is associated with increased risk of developing cancers of the 
postmenopausal breast, colorectum, endometrium, kidney, 
and oesophageal adenocarcinoma. In 2007, the World 
Cancer Research Fund (WRCF) [2] used a more standardised 
approach to review the literature and reported that the 
evidence that body fatness is associated with increased risk 
of oesophageal adenocarcinoma, and with cancers of the 
pancreas, colorectum, postmenopausal breast, endometrium, 
and kidney is convincing, and that a probably association 
exists between body fatness and risk of gallbladder cancer. 
 Extending the above evidence, we recently reported a 
systematic review [3] and standardised meta-analysis of 
prospective observational studies (221 datasets including 
281,137 incident cases) quantifying associations with a 5 
kg/m2 BMI increase and risk of incident cancer for 20 cancer 
types. We demonstrated that associations are: (i) sex- 
specific; (ii) exist for a wider range of malignancies than 
previously thought; and (iii) are broadly consistent across 
geographic populations.  
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 While the above syntheses demonstrate associations, a 
key question (not least for the development of cancer 
prevention strategies) is whether these are causally related. 
The aim of this review was to test the data from our 
systematic review against the nine Bradford-Hill criteria [4, 
5] for judging causal association. Furthermore, investigators 
have argued that additional criteria for assessing causality 
should include adjustment for available confounding factors; 
evaluation of measurement error and study design; and 
assessment of residual confounding [6] – and these too were 
evaluated. 
CAUSAL ASSOCIATION – BRADFORD-HILL CITE-
RIA 
1. Strength of Association 
A Strong Association is More Likely to have a Causal 
Component than is a Modest Association 
 Hill [4] illustrated this point with the high risk ratios for 
the association between exposure levels of smoking and 
incidence of lung cancer. However, he equally demonstrated 
with two counter-examples that the absence of a strong 
association does not rule out a causal effect and recognised 
that the impression of strength of association depended on 
the index used for the magnitude of association. For our 
systematic review, the index was BMI as an approximation 
of body adiposity. As BMI represents a spectrum of 
exposures (rather than a binary exposure), the size of the risk 
estimate is expressed relative to a given change in BMI. 
Accordingly, we chose 5 kg/m2 increments (Table 1), such 
that increases in BMI of 5, 10 and 15 kg/m2 are broadly 
equivalent to World Health Organisation [7] categories - 
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overweight, class I obese, and class II obese. From our meta-
analysis, the point estimates for the top four ranking 
malignancies in men per increases in BMI of 5, 10 and 15 
kg/m2  are: 1.52, 2.04, 2.56 for oesophageal  adenocarcinoma; 
1.33, 1.66, 1.99 for thyroid cancer; and 1.24, 1.48, 1.72 for 
colon and renal cancers, respectively. For women, the point 
estimates for the top four ranking malignancies per increases 
in BMI of 5, 10 and 15 kg/m2 are: 1.22, 1.73, 2.99 for 
endometrial cancer (see section on “biological gradient” 
below); 1.59, 2.18, 2.77 for gallbladder cancer; 1.51, 2.02, 
2.53 for oesophageal adenocarcinoma; and 1.34, 1.68, 2.02 
for renal cancer, respectively.  
 The strength of evidence of an association (based mainly 
on the number of studies and cases) may also be relevant. 
For malignancies with strong associations, estimates were 
based on at least one thousand cases; the exception was 
oesophageal adenocarcinoma in women (n = 735). Associa-
tions for rectal cancer in men and endometrial cancer were 
based on greater than ten thousand cases each; associations 
for colon cancer (both genders) and postmenopausal breast 
cancer were based on twenty thousand cases each. 
 In summary, the associations between increased BMI and 
incident cancer risk are strong for several cancers based on 
size of estimate and number of observed cases. 
Table 1. Summary Estimates for Associations between BMI (per 5 kg/m2 Increment Increase) 
 
MEN WOMEN 
 No. of 
Studies 
No. of 
Cases RR (95% CIs) P I
2 No. of Studies 
No. of 
Cases RR (95% CIs) P I
2 
Colorectal cancer           
     Colon 22 22,440 1.24 (1.20, 1.28) <0.0001 21% 19 20,975 1.09 (1.05, 1.13) <0.0001 39% 
     Rectum 18 14,894 1.09 (1.06, 1.12) <0.0001 3% 14 9052 1.02 (1.00, 1.05) 0.26 0% 
Gastro-oesophageal cancers           
     Gastric 8 817 0.97 (0.88, 1.06) 0.49 35% 5 325 1.04 (0.90, 1.20) 0.56 4% 
     Oesophageal 
adenocarcinoma 5 1315 1.52 (1.33, 1.74) <0.0001 24% 3 735 1.51 (1.31, 1.74) <0.0001 0% 
     Oesophageal squamous cell  
     carcinoma 
3 6201 0.71 (0.60, 0.85) <0.0001 49% 2 1114 0.57 (0.47, 0.69) <0.0001 60% 
Hepatobiliary cancers           
     Gallbladder 4 928 1.09 (0.99, 1.21) 0.12 0% 2 1111 1.59 (1.02, 2.47) 0.04 67% 
     Liver 4 2039 1.24 (0.95, 1.62) 0.12 83% 1 31 1.07 (0.55, 2.08) NA NA 
Leukaemia 7 3371 1.08 (1.02, 1.14) 0.009 0% 7 5317 1.17 (1.04, 1.32) 0.01 80% 
Lung cancer 11 7426 0.76 (0.70, 0.83) <0.0001 63% 6 4273 0.80 (0.66, 0.97) 0.03 84% 
Malignant melanoma 6 3492 1.17 (1.05, 1.30) 0.004 44% 5 4786 0.96 (0.92, 1.01) 0.05 0% 
Multiple myeloma 7 4273 1.11 (1.05, 1.18) <0.0001 7% 6 3664 1.11 (1.07, 1.15) <0.0001 0% 
Non-Hodgkin’s lymphoma 6 7041 1.06 (1.03, 1.09) <0.0001 0% 7 6248 1.07 (1.00, 1.14) 0.05 47% 
Pancreatic cancer 12 2390 1.07 (0.93, 1.23) 0.33 70% 11 2053 1.12 (1.02, 1.22) 0.01 43% 
Renal cancer 11 6073 1.24 (1.15, 1.34) <0.0001 37% 12 4614 1.34 (1.25, 1.43) <0.0001 45% 
Thyroid cancer 4 1212 1.33 (1.04, 1.70) 0.02 77% 3 2375 1.14 (1.06, 1.23) 0.001 5% 
Prostate cancer 27 70,421 1.03 (1.00, 1.07) 0.11 73%      
Breast cancer           
     Pre-menopausal      20 7930 0.92 (0.88, 0.97) 0.001 39% 
     Post-menopausal      31 23,909 1.12 (1.08, 1.16) <0.0001 64% 
Endometrial cancer      19 17,084 1.59 (1.50, 1.68) <0.0001 77% 
Ovarian      13 12,208 1.03 (0.99, 1.08) 0.30 55% 
NA: not applicable. 
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2. Consistency 
A Relationship is Observed Repeatedly 
 For Hill [4], the repeated observation of an association 
included “different persons, places, circumstances and time”. 
Because our meta-analysis [3] used a standardised approach 
to the dose-response analysis – expressed per 5 kg/m2 – we 
circumvented different BMI category cut-off points for Asia-
Pacific populations [8], and showed for the first time that 
positive associations between BMI and risk of several cancer 
Fig. (1). (A) Forest plot of the associations between 5 kg/m2 BMI increase and renal cancer risk in men, stratified by main geographic 
populations. (B) Forest plot of the associations between 5 kg/m2 BMI increase and pre-menopausal breast cancer, stratified by main 
geographic populations. 
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types is broadly consistent across geographic populations. 
An illustration of this is shown for renal cancer in men in 
Fig. (1A). However, there were examples of different 
patterns of associations, notably illustrated by pre-
menopausal breast cancer risk – this association is inverse 
for North American, and European and Australian 
populations, but elevated for Asia-Pacific populations (Fig. 
1B). A possible explanation may be as follows: the risks of 
cardiovascular disease and type 2 diabetes are elevated at 
lower BMI values among Asian populations compared with 
populations of American and European origin [8] due to 
greater percentage body fat per BMI category. In a similar 
manner, the increased risk of premenopausal breast cancer 
among women might be explained by their greater 
percentage of body fat per BMI category, and by 
extrapolation, BMI may be a poor surrogate of adiposity in 
the younger woman of European descent (see also later 
under Coherence). Additionally, there may be differences in 
the patterns and extents of BMI-cancer associations among 
North American Blacks compared with Whites as reported in 
a large study of US Veterans and using obesity on hospital 
discharge as the determinant of exposure [9]. However, risk 
estimates for pre-menopausal breast cancer in one all Black 
American study [10] are similar to those for studies from 
Caucasian populations. These inconsistencies need further 
substantiation. 
 Consistency across studies can be assessed statistically 
using a test of heterogeneity, the I2 statistics [11], as a 
measure of the proportion of total variation in estimates. The 
I2 values of 25%, 50% and 75% correspond to cut-off points 
for low, moderate and high degrees of heterogeneity. 
Between-study heterogeneity was high for thyroid and liver 
cancer in men, and endometrial and lung cancers and 
leukaemia in women; for the remainder, between-study 
heterogeneity was moderate or low indicating consistency of 
associations.  
 In summary, the associations between increased BMI and 
incident cancer risk are broadly consistent across geographic 
populations and generally demonstrate low levels of 
between-study heterogeneity. 
3. Specificity 
A Factor Influences a Particular Outcome or Population 
 For Hill [4], if one observed an association that was 
specific for an outcome or group of individuals, this was a 
strong argument for a causal effect. Of course, in the 
example of BMI and cancer risk, the risk exposure (i.e. 
adiposity) may cause several other diseases (for example, 
type 2 diabetes), and in turn, cancers associated with BMI 
may have multiple risk factors. Despite this, there was clear 
evidence from our meta-analysis [3] that the associations 
between BMI and a given cancer type differed in a sex-
specific manner. This was best illustrated for colon, rectal 
and renal cancers (Table 2). Thus, the associations between 
BMI and colon and rectal cancers were stronger in men 
compared with women; but the reverse was observed for 
renal cancer. Furthermore, for large bowel, associations were 
stronger for colon compared with rectum within the same 
sex. Other examples of specificity included: (i) associations 
for pre-menopausal breast cancer differed for Asia-Pacific 
populations compared with Caucasian North American and 
European/Australian populations; (ii) associations were in 
the main for non-smoking related cancers; and (iii) strengths 
of associations differed across cancer types.  
4. Temporality 
The Factor Must Precede the Outcome it is Assumed to 
Affect 
 Hill [4] introduced this reflection with the proverb 
“which is the cart and which is the horse?”. According to 
Hill, temporal direction might be difficult to establish if a 
disease developed slowly as is the case for most adult 
cancers. It is therefore important to have several years 
duration from BMI determination to cancer diagnosis. To 
assess this in our systematic review [3], we plotted the mean 
follow-up for each study categorised per cancer site – these 
are shown in Fig. (2). The analysis covered approximately 
133 million person-years of follow-up with geometric mean 
follow-up periods varying from 8.8 years (breast cancer) to 
14.4 years (multiple myeloma). The lower confidence 
interval was greater than 7 years for all sites. These durations 
are considerably longer than, for instance, meta-analyses of 
the association between BMI and cardiovascular diseases 
[12, 13] and diabetes risk [14]. These time periods from 
baseline determination of BMI to cancer diagnosis argue 
against confounding such as survival biases and reversal 
causality i.e. the presence of cancer altering body weight. 
The latter may have been a concern if we had included 
conventional case-control studies in our review. 
 
 
Table 2. Comparisons of Risk Ratios in Men and Women for Colon, Rectal and Renal Cancers* 
 
Risk ratio (95% CIs) per 5 kg/m2 increase 
 
Men Women 
P value† 
Colon cancer 1.24 (1.18-1.31) 1.08 (1.02-1.34) <0.0001 
Rectal cancer 1.08 (1.05-1.11) 1.01 (0.98-1.04) 0.003 
Renal cancer 1.18 (1.08-1.29) 1.35 (1.29-1.42) 0.004 
*Risk ratios shown are those where studies reported estimates for both sexes. 
†Meta-regression analysis with multivariate models including the method of BMI determination (measured or self-reported); extent of cancer-site specific risk 
factor adjustment; and geographic population. 
CI: confidence interval. 
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5. Biological Gradient 
The Outcome Increases Monotonically with Increasing 
dose of Exposure or According to a Function Predicted by 
a Substantive Theory 
 Hill [4] favoured linear relationships between exposure 
and outcome, pointing out that if the shape of the dose-
response relationship were a more complex, non-monotonic, 
function, this would require a complex substantive explana-
tion. For example, J-shaped dose-response curves might be 
caused by the respective exposure levels while others might 
be due to confounding. Thus, for example, the relationship 
between BMI and all-cause mortality is J-shaped [15, 16], 
but it has recently become clear through individual-patient 
based analysis of 57 prospective cohorts that the apparent 
increase in mortality at low BMI levels reflects mainly 
smoking-related illnesses [17]. 
 To address this in our systematic review [3], we assessed 
the assumption of linearity visually by plotting the ln[RR] 
for each study BMI category against BMI. The plots 
suggested linear associations for all cancer types. The 
exception was endometrial cancer which was handled as two 
“slopes” pivoted at BMI = 27 kg/m2 (Fig. 3) - this inflection 
was determined using a goodness-of-fit approach in a 
generalised least squares for trends (GLST) estimation model 
as described by Orsini and colleagues [18]. 
 
Fig. (2). Follow-up periods in the systematic review. The horizontal blue lines represent geometric mean per dataset. Data were available for 
174 (out of 185) datasets. The geometric means per site are shown by the purple solid circle. The values for medians were similar. 
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6. Plausibility 
The Observed Association can be Plausibly Explained by 
Substantive (e.g. Biological) Explanations 
 The mechanisms linking excess weight and cancer risk 
are not fully understood (Table 3), though three hormonal 
systems – insulin and insulin-like growth factor (IGF) axis, 
sex steroids, and adipokines – are the most studied candi-
dates [19]. While all three systems are interlinked through 
insulin, their roles may vary between cancer sites. The 
insulin-IGF hypothesis postulates that chronic hyperinsulin-
aemia decreases concentrations of IGF binding proteins -1 
and -2, leading to increased bio-available or free IGF-I with 
concomitant changes in the cellular environment (IGF-I 
increases mitosis, is anti-apoptotic, pro-angiogenic, and 
increases cell motility) favouring tumour formation [20]. 
Circulating total IGF-I, a major determinant of free IGF-I 
concentrations, is also consistently associated with increased 
risk of prostate, colorectal and pre-menopausal breast 
cancers [21], and in some studies of post-menopausal breast 
cancer [22, 23]. Mean circulating concentrations of total 
IGF-I are higher in men than women [24], which may part 
explain some observed differences, for instance, in colorectal 
cancer risk are greater in men compared with women. 
However, the insulin-IGF hypothesis has two fundamental 
inconsistencies – first, levels of total IGF-I increase linearly 
with increasingly BMI but only to a pivotal point around 27 
kg/m2, thereafter declining with increasing weight [20]; 
second, in overweight individuals who intentionally lose 
weight, total IGF-I concentrations tend to increase [25]. 
 For post-menopausal breast cancer, the increase in risk 
might be explained by the higher rates of conversion of and-
rogenic precursors to oestradiol through increased aromatase 
enzyme activity in adipose tissue. In endometrial cancer, 
there may be more than one system involved: increased oes-
tradiol levels not only increase endometrial cell proliferation 
and inhibit apoptosis, but might also stimulate the local 
synthesis of IGF-I in endometrial tissue [26]. Furthermore, 
chronic hyperinsulinaemia may promote tumorigenesis in 
oestrogen-sensitive tissues by reducing blood concentrations 
of sex hormone binding globulin, which in turn, increases 
bio-available oestrogen [26]. Adiposity is inversely related to 
testosterone concentrations in men [27], but positively 
related in women [28], which may be relevant to gender 
differences in the relationship of BMI and cancer risk. 
 Adiponectin is the most abundant adipokine, secreted 
mainly from visceral adipose tissue and is inversely correla-
ted with BMI. In terms of tumour development, this insulin-
sensitising agent is anti-inflammatory; anti-angiogenic; and 
inhibits tumour growth in animal models [29]. Beyond these 
mechanisms other candidate systems include obesity-related 
 
Fig. (3). Relationship of BMI and endometrial cancer risk. The graph shows representation of each study plot of risk versus BMI. Each study 
is a line; the circles represent the risk at the midpoint of each BMI category per study; the size of the circle is proportional to the sample size 
per BMI category. The first author of each study is listed against each plot. The BMI-cancer risk association for endometrial cancer was 
modelled as two “slopes” pivoted at BMI = 27 kg/m2 (green solid line). This inflection was determined using a goodness-of-fit approach in a 
generalised least squares for trends (GLST) model. 
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inflammatory cytokines, altered immune response, oxidative 
stresses, obesity-related hypoxia, adipocyte secreted pro-
angiogenic factors, the nuclear factor κ β system [20], and 
hypertension and lipid peroxidation for renal cancer [30], 
and acid-reflux for oesophageal adenocarcinoma. The 
mechanisms linking adiposity and less common malig-
nancies are speculative. 
Table 3. Candidate Mechanisms Linking Obesity and Cancer 
Risk 
 
Biological mechanisms 
 Insulin and insulin-like growth factors (IGFs) 
 Sex steroids and sex-steroid binding globulin                   Most studied 
 Adipokines (e.g. adiponectin and leptin) 
 Obesity-associated hypoxia 
 Adipocyte secreted pro-angiogenic factors 
 Obesity-related inflammatory cytokines 
 Nuclear factor κB system 
 Altered immune response 
  
Shared genetic susceptibility 
 
Migrating adipose stromal cells 
  
Mechanical mechanisms 
 Hypertension and renal cancer 
 Acid reflux and oesophageal adenocarcinoma 
 Increased iodine uptake and thyroid cancer 
 
 In summary, there are several plausible biological 
explanations for linking adiposity with cancer risk – it is 
likely that not one “hat” fits all and indeed several mecha-
nisms may be operating for some cancer types. 
7. Coherence 
A Causal Conclusion should Not Fundamentally Contra-
dict Present Substantive Knowledge 
 Hill [4] use the term “generally known facts” to indicate 
that the knowledge against which an association is evaluated 
has to be undisputable. The difference in Hill’s definitions of 
plausibility and coherence appears subtle – whereas plausi-
bility is worded positively (an association that should be in 
line with substantive knowledge), coherence is verbalised 
negatively (an association that should not conflict with 
substantive knowledge). This can be exemplified in the 
apparent association of BMI and reduced risk of developing 
pre-menopausal breast cancer (as we saw above, an 
association restricted to Caucasian North American and 
European/Australian populations). Traditional explanation 
has been that greater body fatness may protect against pre-
menopausal breast cancer through a greater number of 
anovulatory menstrual cycles [2]. However, this hypothesis 
fails to be coherent as body fatness expressed as waist 
circumference or waist-hip ratio (as a surrogate of central 
adiposity) is associated with an increased risk of pre-
menopausal breast cancer [31]. A more coherent explanation 
(i.e. one that does not contradict a substantive theory) is that 
BMI is an inappropriate approximation of body adiposity in 
younger women. Importantly, adult attained height is a 
consistent predictor for pre-menopausal breast cancer [32] – 
for this breast cancer subtype (i.e. pre-menopausal), “height” 
may disproportionately influences the BMI formula. For 
example, a short young woman may have a disproportiona-
tely high BMI, which appears protective. 
8. Experiment 
Causation is more Likely if Evidence is Based on 
Randomised Experiments 
 While there are many observational studies of the 
association of BMI and/or weight gain and cancer risk, there 
are only a small number examining the issues of reversibility 
of effect – in other words, is intentional weight loss in 
overweight and/or obese populations associated with reduced 
cancer risk? There are a plethora of studies in animals 
demonstrating that weight loss/calorie restriction is 
protective against tumour development and progression [33, 
34]. However, in humans, there are no randomized data on 
this issue; data in the main comes from secondary analyses 
of large observational cohort studies. Most studies have been 
pertinent to risk reduction of breast cancer [35-41], with 
smaller numbers of studies on risk reduction of endometrial 
[42] and prostate cancers [43]. The emphasis on studies in 
breast cancer, however, serves to demonstrate that the 
question of reversibility is not trivial. First, for most 
(westernised) female populations, there is a steady increase 
in mean weight after the 20th birthday through into the post-
menopausal women [44]. In other words, the “baseline” 
mean weight is a “moving target”, and what may be 
considered a weight reduction to a normal BMI category in 
one age group, may be maintenance of normal weight in 
another. Second, all studies to-date (even if they are cohort 
in design) have relied on recall methods to determine 
weights in younger adult age groups; such approaches may 
be subject to bias. Third, within these cohorts, there are three 
broad questions: (i) is weight loss in later reproductive years 
associated with reduced risk of post-menopausal breast 
cancer risk; (ii) is weight loss in early adult years associated 
with reduced risk of post-menopausal breast cancer; and (iii) 
is weight loss in early adult years associated with reduced 
risk of pre-menopausal breast cancer risk - and not all three 
are addressed in all papers. Accepting these limitations and 
difference in study design, the following observations can be 
stated for breast cancer: (i) weight loss in later reproductive 
years is associated with reduced risk of post-menopausal 
breast cancer risk in some [36, 40] but not all studies [37-39, 
41]; (ii) weight loss in early reproductive years appears to 
reduce risk of post-menopausal breast cancer in most studies 
[35, 37, 38,41]; and (iii) whether or not weight loss in early 
reproductive years is associated with reduced risk of pre-
menopausal breast cancer risk is equivocal as the data are 
sparse [39].  
 By contrast with population-based cohort studies (where 
weight reductions are generally modest and may not be 
sustained), post-bariatric surgery patients (morbidly obese: 
BMI ≥ 40 kg/m2) experience significant and sustained 
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weight loss (typically 20 kg) and offer a unique population to 
explore the effects of long-term voluntary weight loss on 
cancer. Data, recently been published from the Swedish 
Obesity Study [45], a prospective controlled interventional 
trial and with greater than 10 years median follow-up, show 
that bariatric surgery is associated with a reduced risk of 
developing cancers. Similar findings are also seen in three 
retrospective North American cohorts [46-48]. Interestingly, 
the beneficial effects of bariatric surgery on cancer incidence 
reduction appear to be limited to women [49]. 
9. Analogy 
For Analogous Exposures and Outcomes An Effect has 
already been Shown 
 Hill [4] wrote that it would be sometimes acceptable to 
“judge by analogy”. Susser [50] interpreted Hill as claiming 
that “when one class of causal agents is known to have 
produced an effect, the standards for evidence that another 
agent of that class produces a similar effect can be reduced”. 
At one level, it is difficult to apply “obesity” to a class of 
agent – however, at another level obesity may be considered 
to represent an altered physiological state typically charac-
terised by an excess hormonal environment. In this setting, 
there are analogies in the human literature where excessive 
physiological exposures of hormones are associated with 
cancer risk: acromegaly (a chronic endocrine disorder 
characterised by sustained hypersecretion of growth 
hormone) is associated with increased risk of colorectal and 
thyroid cancers [51]; and hormonal replacement therapy is 
associated with increased risk of breast cancer in a time-
dependent manner [52].  
 An alternative view of analogy is: are there others 
settings where there is evidence that the risk exposure of 
interest is causally implicated in other diseases. Thus, for 
obesity, there is strong evidence through interventions such 
as bariatric surgery that obesity is implicated in the causation 
of cardiovascular disease and type 2 diabetes [53]. 
OTHER STUDY ATTRIBUTES AND CAUSAL 
ASSOCIATION 
Appropriate Adjustment for Available Confounding 
Factors 
 Many of the original studies included in our systematic 
review [3] were not primarily designed with cancer 
occurrence as the primary endpoint. Thus, while many 
studies measured potential confounding factors relevant to 
the primary disease of interest, these factors may not have 
been relevant to the specific cancer being reported. We 
therefore listed each factor adjusted per study and classified 
these as whether or not it was relevant to the predisposition 
of that cancer i.e. cancer site-specific risk factor (CSS-RF), 
modified from the lists of risk factors tabulated in the IARC 
World Cancer Report [54]. For each site, the median number 
of CSS-RFs was calculated, and a categorical variable 
generated indicating above and below this median. When 
this dichotomized variable was entered into models of 
association for men and women, it was not significant, 
supporting the notion that appropriate adjustment for 
available confounding factors did not influence our findings. 
Measurement Error and Study Design 
 Our meta-analysis [3] showed that the method of BMI 
determination (self-reported versus direct measurement of 
height and weight) influenced estimates of the BMI-cancer 
risk association in women, but not in men. Studies using 
self-reported determination of height and weight to calculate 
BMI tended to overestimate associations between BMI and 
cancer risk (at least in women) by an average of 0.10 of a 
relative risk. This is not surprising as self-reported of weight 
is known to underestimate true body weight; in turn, 
misclassification varies with age (increases in older 
individuals) and relative BMI (increases with increasing 
BMI) [55].  
Assessment of Residual Confounding 
 It is almost impossible to totally exclude residual 
confounding in observational studies. However, our review 
[3] served to show that it is possible to demonstrate 
confounding that precludes the correct interpretation and 
further analysis of a risk factor exposure association. In the 
example of lung cancer, higher BMI appeared to be 
negatively associated with the risk of lung cancer – an 
observation that could be incorrectly interpreted that being 
obese protects against lung cancer. Analysis published in the 
supplemental files of our meta-analysis [3] showed: (i) the 
apparent “protective” association between BMI and lung 
cancer was largest the greater the proportion of ever-smokers 
for a given study; and (ii) analysis of studies where 
associations were stratified by smokers and non-smokers, it 
became apparent that the inverse association between BMI 
and lung cancer was limited to smokers. This is perhaps not 
too surprising as smokers have lower BMIs compared with 
age and sex-matched non-smokers [56], and of course, 
smoking is a major risk factor for lung cancer.  
 Sensitivity analyses can be undertaken to give an 
indication of the probable effect for included confounders, 
and of the probable effect of measurement error for included 
confounders, and of unmeasured confounders [57]. For 
unmeasured confounders, various plausible values for the 
strength of associations between the unmeasured confounder 
and outcome can be used and a series of fully adjusted 
exposure-outcome associations can be estimated. If these 
estimated associations are only moderately attenuated, 
unmeasured confounders are unlikely to be a major issue. In 
the sensitivity analysis of our review [3], we compared 
summary estimates per cancer site using minimally-adjusted 
versus maximally-adjusted risk estimates from studies. We 
found that there was little difference, supporting the notion 
that there was little residual confounding in our observations 
of the associations between BMI and sex-specific cancer 
risk. 
Lack of Alternative Explanations 
 Conceivably, the associations of BMI and cancer risk 
might be explained through “bystander effects”. Thus, for 
example, it is well recognised that BMI increases with 
increasing age, and in-turn, risk of many adult cancers 
increase with age [44] – raising the question: is increased 
BMI simply a function of age and not a causative risk factor 
for cancer. We addressed this in our systematic review [3] 
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through examining plots of baseline mean ages in studies 
with subsequent risk – there appears to be no relationship. 
This is illustrated for post-menopausal breast cancer in Fig. 
(4).  
 A similar type of question may be: individuals who eat 
energy-dense food, such as fats, develop obesity; is it not the 
fatty foods rather than the state of adiposity per se which is 
relevant? Dietary fat content has been studied for almost four 
decades in relation to risk of breast and colorectal cancers, 
but extensive reviews of these data yield no definitive (but 
lots of inconsistent) evidence of association [2]. 
 Finally, like any review of the literature, there is the risk 
of publication bias. In our systematic review [3], there was 
evidence for funnel plot asymmetry for colon cancer in men 
and women, with smaller studies showing larger effects of 
BMI (p = 0.002 and 0.006, respectively) but little evidence 
for the other cancer types. We tested the potential effect of 
small studies on these estimates by repeating the analyses for 
colon cancer associations excluding studies less than 150 
cases – there was no influence on summary estimates, 
suggesting that publication patterns were unlikely to be a 
major source of bias. 
CONCLUSION 
 In an ideal world, prospective trans-generational observa-
tional studies would establish accurate measures of exposure, 
through repeated measurements of that exposure, from early 
life until the event of interest and/or death [58]. Of course, 
no such study exists to address the exposure of excess body 
weight and cancer risk. Thus, it is only possible to infer 
through indirect data the answer to questions like: is 
childhood obesity per se pertinent to the development of 
adult cancers; when in the life-course pathway, is weight 
gain relevant, and is this different for men and women, and 
across different sites. As we develop cohorts that approach 
life-course models (rather than the current snap-shot 
approach), we will have to in parallel develop statistical 
approaches to best characterise and quantify the cumulative 
effect of the exposure of excess body weight. 
 In this review, we tested available data on the association 
of BMI and cancer risk (collected through a large multi-
cancer type systematic review) against the Bradford-Hill 
criteria of causal association. The findings argue that the data 
support strength of association, consistency, specificity, 
temporality, biological gradient, plausibility, coherence and 
probably analogy. However, the experimental evidence 
supporting reversibility is currently lacking, though indirect 
evidence from longitudinal data in cohort studies and long-
term follow-up post-bariatric surgery is emerging. We addi-
tionally assessed these data against appropriate adjustment 
for available confounding factors; measurement error and 
study design; and residual confounding, and found lack of 
alternative explanations.  
 It is not suggested that any of these criteria in itself is 
necessary or sufficient for causality to be declared, but each 
strengthens the evidence in its favour. Accordingly, we 
conclude that there is considerable evidence to support a 
causal association between BMI and risk for many cancer 
types, but in order to establish the role of weight control in 
cancer prevention, there is a need to develop trial 
frameworks in which to better test reversibility. 
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